Mirikizumab Induction Therapy Achieves Early Clinical, Endoscopic, and Biomarker Improvement in Children and Adolescents with Moderately to Severely Active Ulcerative Colitis: Week 12 Results From the SHINE-2 Study (Late-Breaking Abstract) (ACG 2026) - Sep 25, 2026 - Abstract #71; Pres time: Oct 14, 2026; 09:20 AM - 09:30 AM; Location: Karl F. Dean Grand Ballroom B (Level 4); "Abstract text will be released on Sunday, October 11, 2026, at 12:00 pm CT (1:00 pm ET) when the ACG 2026 embargo lifts."
Biomarker • Clinical • Late-breaking abstract • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
|
|
Marla C. Dubinsky, MD (she/her/hers)
|